Acne, Centella, Melasma, Rosacea
Conditions
Brief summary
The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.
Interventions
OTHERFace mask containing Centella sinensis
A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma; 2. Over 18 years of age; 3. Be able to follow the treatment rules of the study and be followed for 8 weeks; 4. Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders 6.No medication was used within 1 month
Exclusion criteria
1. Currently pregnant, planning to become pregnant or breastfeeding; 2. Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products; 3. Participate in other clinical studies within 3 months before the start of the study; 4. Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances; 5. Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions; 6. Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs) 7. Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical erythema Score (CEA) | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. | Clinical erythema score (CEA) was divided into no, mild, moderate and severe according to the severity of rosacea, corresponding to 0,1,2,3, respectively. |
| Global Aesthetic Improvement Scale Score (GAIS) | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. | The Global Aesthetic Improvement Scale (GAIS) score was evaluated by the treating physician and divided into four levels: very improved corresponding, substantial improvement, improvement, no change; Corresponding to the best beauty effect, significant improvement but not the best, significant improvement, no change; |
| Melasma Area and Severity Rating (MASI) | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. | The melasma Area and Severity Rating (MASI) is used to evaluate the severity of melasma. Melanin deposition was quantitatively evaluated from three aspects: area, color depth and color uniformity. Area weight: Forehead 30%, left cheek 30%, right cheek 30%, mandibular 10%, color plaque proportion (A) \< 10% recorded 1 points, 10% \ 29% recorded 2 points, 30% \ 49% recorded 3 points, 50% \ 69% recorded 4 points, 70% \ 89% recorded 5 points, 90% \ 100% recorded 6 points; Color depth (D), color uniformity (H) scores range from 0 to 4 points, no score 0 points, slight score 1 points, moderate score 2 points, obvious score 3 points, maximum score 4 points. MASI score = forehead \[0.3A (D+H)\]+ right cheek \[0.3A (D+H)\]+ left cheek \[0.3A (D+H)\]+ mandibular \[0.1A (D+H)\], score range 0 \ 48, score was positively correlated with melanin deposition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Quality of Life Score (DLQI) | Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment. | The Dermatology Life Quality Score (DLQI) is scored by answering multiple questions in which patients self-rate the impact of their current illness on their lives over a period of one week. The answer is divided into four levels, very serious 3 points, severe 2 points, a little 1 point, no 0 points; ' |
Countries
China
Contacts
Primary Contactjie dai
Outcome results
None listed